Hypha Labs pivots to Micropearl, burns cash with zero revenue and heavy dilution risk

Hypha Labs, Inc. (OTCBB: DIGP)

What's happening: the company completed its exit from cannabis lab testing (Digipath Labs sale), is pivoting to a consumer product (Hypha Micropearl accelerator) and is burning cash while funding R&D and corporate costs. Management warns of going-concern risk.

Key facts & statistics (from 10‑Q, periods ended June 30, 2025)
* Cash: $147,192
* Total assets: $454,103 (vs $493,805 at 9/30/24)
* Total current liabilities: $2,186,704 (vs $1,393,660 at 9/30/24)
* Total liabilities: $2,186,704
* Stockholders' deficit: $(2,066,201)
* Accumulated deficit: $(23,090,912)
* Negative working capital: $1,846,324 (Note 2 - going concern)
* Revenues: $0 for the three- and nine-month periods ended 6/30/2025
* Operating loss (9 months): $2,510,453
* Net loss from continuing operations (9 months): $2,543,486
* Net loss per share from continuing operations (9 months) - basic: $(0.02)
* Weighted average common shares outstanding - basic (9 months): 130,817,429
* Shares outstanding reported as of Aug 21, 2025: 145,121,825
* Convertible notes payable (total): $1,208,235 (current maturities)
* Notes payable - current maturities: $275,733
* Stock‑based compensation (9 months): $1,737,478
* Potential dilution noted: 108,823,464 shares issuable on conversion of convertible notes payable (anti‑dilutive in computing EPS but a real dilution risk)
* Options outstanding: 13,920,000; Warrants outstanding: 17,387,050

Positive items
* Cash increased from $91,166 to $147,192 (short-term improvement).
* Net cash used in operating activities improved materially: $(64,912) for 9 months 2025 vs $(598,029) in 2024 - lower cash burn in operating cash flows.
* Management has extended debt maturities (subsequent events): convertible note and secured facility maturities extended to July 31, 2027 via deferred payments (reduces immediate liquidity pressure).
* One-time proceeds from the prior sale of Digipath Labs produced cash in 2024 and a prior gain that improved liquidity then; company is investing in a new product (Hypha Micropearl) with evident commercialization plans (targeting market by end of 2025).
* Much of recent expense is non‑cash stock‑based compensation, which preserves cash short term.

Negative items (income-statement / financial health)
* Zero revenue in the quarter and nine months ended 6/30/2025 - no operating sales while burning cash on corporate and development activities.
* Operating expenses jumped: total operating expenses for 9 months $2,510,453 - professional fees and G&A rising (professional fees include $1,737,478 stock comp).
* Large recurring net loss: continuing operations net loss $2,543,486 (9 months) - loss widened significantly vs prior year.
* Current liabilities far exceed current assets (total current assets $340,380 vs current liabilities $2,186,704) - severe short-term liquidity mismatch.
* Significant convertible debt and potential dilution: convertible notes of $1.21M and >108M possible shares tied to conversions - a material dilution overhang.
* Stockholders' deficit $(2,066,201) and accumulated deficit >$23M - capital erosion and shareholder value impairment.
* Management discloses substantial doubt about ability to continue as a going concern without new funding.

Inside the company (operational & governance moves)
* Business pivot: after selling Digipath Labs, the company rebranded to Hypha Labs and formed Hypha Products Inc. to develop the Hypha Micropearl home accelerator (consumer product) - R&D and testing underway.
* Non-cash compensation and equity issuances: Series C preferred (1,000 shares) was issued to the CEO for $100 cash but recorded with excess value of $968,356 as compensation; the company issued large blocks of common stock to consultants and directors (millions of shares) and granted options and warrants - these conserve cash but dilute holders.
* Spending profile: professional and legal/consulting fees rose sharply as the company restructured and pursues new business; that increased operating losses.
* Financing activity: small note and convertible note proceeds in 2025 ($115,600 notes payable, $130,000 convertible note) partially offset costs; lenders and noteholders have agreed to maturity extensions with small deferred payments (reduces immediate defaults but increases long-term obligations).

Bottom line / what to watch
* Immediate priorities: (1) secure new capital or revenue to cover current liabilities and fund product launch, (2) manage dilution from convertible notes/options/warrants, (3) demonstrate product progress and sales traction for the Hypha Micropearl.
* Risk profile: high - no revenue, material negative working capital, heavy potential dilution, and a formal going‑concern disclosure. Investors should treat DIGP as a speculative turnaround/pivot play until the company shows revenues, a sustainable cash runway, or substantial financing that doesn't over-dilute existing holders.

Source: Hypha Labs, Inc. Form 10‑Q for quarter ended June 30, 2025 (figures quoted as reported).